Alpha-1 Detection Resources

Alpha-1 deficiency is a serious hereditary condition that is frequently underrecognized or misdiagnosed. According to a survey by Campos et al (2005) of 1,020 patients with Alpha-1 deficiency, the disease has taken an average of 8.3 years to diagnose from symptom onset. One-third of patients saw more than 2 physicians before being diagnosed.1

To facilitate the diagnosis and treatment of alpha-1 deficiency, CSL Behring is pleased to offer the Making a Clear Diagnosis brochure.

An informative brochure that:

  • Describes the clinical manifestations of Alpha-1 deficiency
  • Presents guidelines for screening and testing your COPD patients for Alpha-1 deficiency and for counseling and treating patients with Alpha-1 deficiency.

Proper diagnosis can make a real difference in the lives of patients and their families. Join us in helping reduce the time to diagnosis for Alpha-1 deficiency, to ensure patients receive treatment as soon as possible.

Call your local CSL Behring representative today to request this brochure and other detection resources. To get the name of your CSL Behring representative, please call 1-866-ZEMAIRA (1-866-936-2472).

CSL Behring and our predecessor companies have a long history of commitment to education and support for our physician and patient communities. We are proud to offer our services and be at your disposal as an ongoing resource, an advisor, and provide educational support to help make your diagnostic practices easier.

Important Safety Information

Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema.

Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.

As with other Alpha-1 therapies, Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For more information about Zemaira®, please see the full prescribing information.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. Campos MA, Wanner A, Zhang G, Sandhaus RA. Chest. 2005;128(3):1179-1186.